BC038822 activators represent a category of compounds that have been identified to enhance the activity of the BC038822 protein. The process of discovering these activators typically starts with a comprehensive high-throughput screening (HTS) approach. This method involves the testing of vast libraries of chemical compounds to identify those that can increase the activity of BC038822. Assays used in HTS are designed to be sensitive and provide quantitative results, usually through detectable changes in fluorescence, luminescence, or absorbance that are indicative of BC038822 activation. Compounds that exhibit the ability to boost the activity of BC038822 are carefully selected for further analysis. To ensure the reliability of the HTS findings, these compounds are then put through a series of secondary assays. These are more refined tests that specifically verify the activation effect on BC038822, ruling out non-specific interactions or false positives that can arise during the initial screening.
After the first selection of BC038822 activators from the HTS and confirmation through secondary assays, the focus shifts to a thorough characterization of their interaction with the BC038822 protein. Structural biology techniques such as X-ray crystallography or NMR spectroscopy are employed to discern the binding mechanism between the activators and BC038822. This is crucial for understanding the precise molecular interactions that stimulate BC038822 activity. Additionally, biophysical methods like surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are utilized to quantify the binding kinetics and affinity between the activators and BC038822. These measurements are essential to grasp how readily and strongly the activators interact with the protein target. Structure-activity relationship (SAR) studies follow, where chemical modifications are systematically introduced into the activator molecules. These studies are key for identifying the structural features that are critical for the activation of BC038822. Modifications based on SAR findings can significantly improve the efficiency with which these compounds activate BC038822.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC) which could enhance the activity of "BC038822" if it is a substrate or associated with PKC-mediated signaling pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium levels, potentially activating calcium-dependent proteins and could enhance the activity of "BC038822" if it is involved in calcium signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A polyphenol that may inhibit certain kinases, potentially modulating signaling pathways to enhance "BC038822" activity if it is negatively regulated by those kinases. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor which could enhance the activity of "BC038822" if it plays a role in PI3K/Akt signaling by modulating downstream effects. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could shift signaling pathways to enhance the activity of "BC038822" if it is associated with MAPK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK1/2 which could lead to the enhancement of "BC038822" activity if it is part of the ERK pathway and regulated by MEK activity. | ||||||
NAD+, Free Acid | 53-84-9 | sc-208084B sc-208084 sc-208084A sc-208084C sc-208084D sc-208084E sc-208084F | 1 g 5 g 10 g 25 g 100 g 1 kg 5 kg | $57.00 $191.00 $302.00 $450.00 $1800.00 $3570.00 $10710.00 | 4 | |
As a coenzyme in redox reactions, NAD+ could enhance the activity of "BC038822" if it is involved in energy metabolism or acts as a substrate for ADP-ribosylation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
A sirtuin activator that could enhance "BC038822" activity if it is involved in pathways affected by sirtuin regulation, such as DNA repair or metabolism. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
A histone deacetylase inhibitor that could enhance the activity of "BC038822" if it is regulated by chromatin remodeling or gene expression changes. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
May increase intracellular zinc levels, which could enhance "BC038822" activity if it has a zinc-binding domain or is involved in zinc-dependent signaling. | ||||||